RS55224B1 - N1-pirazolospiroketon acetil-coa karboksilaza inhibitori - Google Patents
N1-pirazolospiroketon acetil-coa karboksilaza inhibitoriInfo
- Publication number
- RS55224B1 RS55224B1 RS20160845A RSP20160845A RS55224B1 RS 55224 B1 RS55224 B1 RS 55224B1 RS 20160845 A RS20160845 A RS 20160845A RS P20160845 A RSP20160845 A RS P20160845A RS 55224 B1 RS55224 B1 RS 55224B1
- Authority
- RS
- Serbia
- Prior art keywords
- oxo
- isopropyl
- carbonyl
- piperidin
- tetrahydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38810210P | 2010-09-30 | 2010-09-30 | |
| PCT/IB2011/054119 WO2012042433A1 (en) | 2010-09-30 | 2011-09-20 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS |
| EP11768163.5A EP2621493B1 (en) | 2010-09-30 | 2011-09-20 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS55224B1 true RS55224B1 (sr) | 2017-02-28 |
Family
ID=44789556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20160845A RS55224B1 (sr) | 2010-09-30 | 2011-09-20 | N1-pirazolospiroketon acetil-coa karboksilaza inhibitori |
Country Status (15)
| Country | Link |
|---|---|
| US (8) | US8859577B2 (enExample) |
| EP (1) | EP2621493B1 (enExample) |
| JP (1) | JP5824055B2 (enExample) |
| CA (1) | CA2811033C (enExample) |
| CY (1) | CY1118016T1 (enExample) |
| DK (1) | DK2621493T3 (enExample) |
| ES (1) | ES2602111T3 (enExample) |
| HR (1) | HRP20161178T1 (enExample) |
| HU (1) | HUE031616T2 (enExample) |
| LT (1) | LT2621493T (enExample) |
| PL (1) | PL2621493T3 (enExample) |
| PT (1) | PT2621493T (enExample) |
| RS (1) | RS55224B1 (enExample) |
| SI (1) | SI2621493T1 (enExample) |
| WO (1) | WO2012042433A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040198483A1 (en) | 2003-04-03 | 2004-10-07 | Amaitis Lee M. | System and method for betting on a subset of participants in an event |
| US9098883B2 (en) | 2004-02-03 | 2015-08-04 | Cantor Index, Llc | Managing bets that select events and participants |
| US8636571B2 (en) | 2004-02-03 | 2014-01-28 | Cantor Index, Llc | System and method for managing select five horseracing bets |
| EP2297163B1 (en) | 2008-05-28 | 2015-07-08 | Pfizer Inc. | Pyrazolospiroketone acetyl-CoA carboxylase inhibitors |
| CA2778886C (en) | 2009-11-10 | 2014-01-07 | Pfizer Inc. | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| PT2621493T (pt) | 2010-09-30 | 2016-11-14 | Pfizer | Inibidores de n1-pirazolospirocetona acetil-coa carboxilase |
| PL2632925T3 (pl) * | 2010-10-29 | 2015-10-30 | Pfizer | N1/N2-laktamowe inhibitory karboksylazy acetylo-CoA |
| EA022375B1 (ru) * | 2011-04-22 | 2015-12-30 | Пфайзер Инк. | ПРОИЗВОДНЫЕ ПИРАЗОЛОСПИРОКЕТОНОВ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ |
| US8905832B2 (en) | 2012-01-30 | 2014-12-09 | Cfph, Llc | Event wagering with group and/or in run options |
| US11055967B2 (en) | 2014-03-26 | 2021-07-06 | Cfph, Llc | Event wagering with group and/or in run options |
| US20170178994A1 (en) * | 2015-12-21 | 2017-06-22 | Intel Corporation | Integrated circuit package support structures |
| KR102579876B1 (ko) | 2016-02-22 | 2023-09-18 | 삼성전자주식회사 | 반도체 패키지 |
| CA3058542A1 (en) * | 2017-04-18 | 2018-10-25 | Genfit | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor |
| HUE061885T2 (hu) * | 2017-11-21 | 2023-08-28 | Pfizer | 4-(4-(4-(1-Izopropil-7-oxo-1,4,6,6,7-tetrahidrospiro[indazol-5,4'-piperidin] -1'-karbonil)-6-metoxipiridin-2-il)-benzoesav kristályos 2-amino-2-(hidroximetil)-propán-1,3-diol sója |
| US10934279B2 (en) | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| WO2020044266A1 (en) * | 2018-08-31 | 2020-03-05 | Pfizer Inc. | Combinations for treatment of nash/nafld and related diseases |
| CA3140972C (en) * | 2019-05-20 | 2024-06-18 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| CN110183456A (zh) * | 2019-07-11 | 2019-08-30 | 河南师范大学 | 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法 |
| KR20220112811A (ko) | 2019-12-10 | 2022-08-11 | 화이자 인코포레이티드 | 2-((4-((S)-2-(5-클로로피리딘-2-일)-2-메틸벤조[d][1,3]디옥솔-4-일)피페리딘-1-일)메틸)-1-(((S)-옥세탄-2-일)메틸)-1H-벤조[d]이미다졸-6-카르복실산, 1,3-디히드록시-2-(히드록시메틸)프로판-2-아민 염의 고체 형태 |
| CA3166630A1 (en) | 2020-01-03 | 2021-07-08 | Berg Llc | Polycyclic amides as ube2k modulators for treating cancer |
| PH12022552056A1 (en) | 2020-02-07 | 2024-02-12 | Gasherbrum Bio Inc | Heterocyclic glp-1 agonists |
| JP2021134211A (ja) | 2020-02-24 | 2021-09-13 | ファイザー・インク | Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ |
| JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| WO2021191812A1 (en) | 2020-03-27 | 2021-09-30 | Pfizer Inc. | Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| CA3230347A1 (en) | 2021-08-31 | 2023-03-09 | Pfizer Inc. | Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
| CN119137124A (zh) | 2022-03-09 | 2024-12-13 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| CN119255988A (zh) | 2022-04-14 | 2025-01-03 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| EP4605076A1 (en) | 2022-10-18 | 2025-08-27 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
| WO2024125602A1 (en) | 2022-12-15 | 2024-06-20 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
| WO2025099561A1 (en) | 2023-11-07 | 2025-05-15 | Pfizer Inc. | Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| WO2025224648A1 (en) | 2024-04-26 | 2025-10-30 | Pfizer Inc. | Oral compositions/formulations of 2-({4-[(2s)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0901786B1 (en) | 1997-08-11 | 2007-06-13 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
| JP4104983B2 (ja) | 2001-02-28 | 2008-06-18 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体作動薬としてのアシル化ピペリジン誘導体 |
| EP1478437B1 (en) | 2002-02-27 | 2005-08-31 | Pfizer Products Inc. | Acc inhibitors |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| JPWO2004092179A1 (ja) | 2003-04-14 | 2006-07-06 | 日本曹達株式会社 | スピロ誘導体、製造法および抗酸化薬 |
| JP2005119987A (ja) | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| US20050267221A1 (en) | 2004-05-14 | 2005-12-01 | Research Development Foundation | Use of curcumin and analogues thereof as inhibitors of ACC2 |
| BRPI0510273A (pt) | 2004-05-25 | 2007-10-30 | Pfizer Prod Inc | derivados de tetraazabenzo[e]azuleno e análogos destes |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| US7410976B2 (en) | 2005-07-19 | 2008-08-12 | Merck & Co., Inc. | Spirochromanone derivatives |
| EP1911753A1 (en) | 2005-07-29 | 2008-04-16 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
| DE102006016566B4 (de) | 2005-09-22 | 2008-06-12 | Beru Ag | Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren |
| EP1951251B1 (en) | 2005-11-18 | 2010-12-29 | Merck Sharp & Dohme Corp. | Spirohydantoin aryl cgrp receptor antagonists |
| CN101384568B (zh) | 2006-02-15 | 2012-12-12 | 雅培制药有限公司 | 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 |
| EP2097420B1 (en) | 2006-11-29 | 2012-04-04 | Pfizer Products Inc. | Spiroketone inhibitors of acetyl-coa carboxylase |
| CA2674530C (en) * | 2007-01-12 | 2014-09-16 | Banyu Pharmaceutical Co., Ltd. | Spirochromanon derivatives |
| PE20081559A1 (es) | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
| WO2008102749A1 (ja) | 2007-02-20 | 2008-08-28 | Takeda Pharmaceutical Company Limited | 複素環化合物 |
| JP5404601B2 (ja) | 2007-04-12 | 2014-02-05 | ファイザー・インク | 新規な３−アミド−ピロロ［３，４−ｃ］ピラゾール−５（１Ｈ，４Ｈ，６Ｈ）カルバルデヒド誘導体 |
| US7981904B2 (en) | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
| EP2297163B1 (en) * | 2008-05-28 | 2015-07-08 | Pfizer Inc. | Pyrazolospiroketone acetyl-CoA carboxylase inhibitors |
| EP2297164A1 (en) | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| WO2010002010A1 (en) * | 2008-07-04 | 2010-01-07 | Banyu Pharmaceutical Co.,Ltd. | Novel spirochromanone carboxylic acids |
| US8110570B2 (en) | 2008-07-14 | 2012-02-07 | Cropsolution, Inc. | Modulators of acetyl-coenzyme A carboxylase and methods of use thereof |
| CA2778886C (en) * | 2009-11-10 | 2014-01-07 | Pfizer Inc. | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| CA2778316A1 (en) * | 2009-11-10 | 2011-05-19 | Pfizer Inc. | N-2 pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| PT2621493T (pt) * | 2010-09-30 | 2016-11-14 | Pfizer | Inibidores de n1-pirazolospirocetona acetil-coa carboxilase |
| US20160034775A1 (en) | 2014-08-02 | 2016-02-04 | General Vault, LLC | Methods and apparatus for bounded image data analysis and notification mechanism |
-
2011
- 2011-09-20 PT PT117681635T patent/PT2621493T/pt unknown
- 2011-09-20 LT LTEP11768163.5T patent/LT2621493T/lt unknown
- 2011-09-20 ES ES11768163.5T patent/ES2602111T3/es active Active
- 2011-09-20 PL PL11768163T patent/PL2621493T3/pl unknown
- 2011-09-20 CA CA2811033A patent/CA2811033C/en active Active
- 2011-09-20 HU HUE11768163A patent/HUE031616T2/hu unknown
- 2011-09-20 DK DK11768163.5T patent/DK2621493T3/en active
- 2011-09-20 HR HRP20161178TT patent/HRP20161178T1/hr unknown
- 2011-09-20 JP JP2013530829A patent/JP5824055B2/ja active Active
- 2011-09-20 EP EP11768163.5A patent/EP2621493B1/en active Active
- 2011-09-20 RS RS20160845A patent/RS55224B1/sr unknown
- 2011-09-20 US US13/876,211 patent/US8859577B2/en active Active
- 2011-09-20 SI SI201130951A patent/SI2621493T1/sl unknown
- 2011-09-20 WO PCT/IB2011/054119 patent/WO2012042433A1/en not_active Ceased
-
2014
- 2014-09-19 US US14/491,016 patent/US9145416B2/en active Active
-
2015
- 2015-09-11 US US14/851,572 patent/US20150376185A1/en not_active Abandoned
-
2016
- 2016-08-15 US US15/236,635 patent/US9908883B2/en active Active
- 2016-09-13 CY CY20161100905T patent/CY1118016T1/el unknown
-
2018
- 2018-01-30 US US15/883,109 patent/US10294225B2/en active Active
-
2019
- 2019-04-01 US US16/371,896 patent/US10822335B2/en active Active
-
2020
- 2020-09-28 US US17/034,295 patent/US11673890B2/en active Active
-
2023
- 2023-05-03 US US18/311,715 patent/US20230322777A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20161178T1 (hr) | 2016-11-04 |
| LT2621493T (lt) | 2016-10-25 |
| CA2811033A1 (en) | 2012-04-05 |
| PT2621493T (pt) | 2016-11-14 |
| WO2012042433A1 (en) | 2012-04-05 |
| SI2621493T1 (sl) | 2016-10-28 |
| US20190218218A1 (en) | 2019-07-18 |
| US9908883B2 (en) | 2018-03-06 |
| US10822335B2 (en) | 2020-11-03 |
| EP2621493B1 (en) | 2016-08-17 |
| EP2621493A1 (en) | 2013-08-07 |
| US20160347752A1 (en) | 2016-12-01 |
| US20130190334A1 (en) | 2013-07-25 |
| ES2602111T3 (es) | 2017-02-17 |
| US8859577B2 (en) | 2014-10-14 |
| US9145416B2 (en) | 2015-09-29 |
| US20210047325A1 (en) | 2021-02-18 |
| US20230322777A1 (en) | 2023-10-12 |
| DK2621493T3 (en) | 2016-10-24 |
| US10294225B2 (en) | 2019-05-21 |
| US11673890B2 (en) | 2023-06-13 |
| JP5824055B2 (ja) | 2015-11-25 |
| US20150011470A1 (en) | 2015-01-08 |
| CA2811033C (en) | 2015-10-20 |
| US20180162858A1 (en) | 2018-06-14 |
| PL2621493T3 (pl) | 2017-01-31 |
| CY1118016T1 (el) | 2017-05-17 |
| JP2013540119A (ja) | 2013-10-31 |
| US20150376185A1 (en) | 2015-12-31 |
| HUE031616T2 (hu) | 2017-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11673890B2 (en) | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | |
| US8288405B2 (en) | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | |
| US20150152109A1 (en) | N1/n2-lactam acetyl-coa carboxylase inhibitors | |
| MX2013012313A (es) | Derivados de pirazoloespirocetona para usarse como inhibidores de acetil-coa carboxilasa. | |
| US20120225900A1 (en) | N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors |